Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial

No authors listed

Published Erratum

No authors listed. Eur Heart J Cardiovasc Pharmacother. 2024.

. 2024 Aug 14;10(5):478.

doi: 10.1093/ehjcvp/pvae046.

No abstract available

Erratum for

Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.
Obayashi Y, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tokuyama H, Sakamoto H, Fujita T, Nanasato M, Okayama H, Nishikura T, Kirigaya H, Nishida K, Ono K, Kimura T; STOPDAPT-3 investigators. Obayashi Y, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):374-390. doi: 10.1093/ehjcvp/pvae009. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38285607 Clinical Trial.